The Insulin Cost Reduction Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Oct 19, 2021)
The Insulin Cost Reduction Act
This bill prohibits the negotiation of price concessions between insulin manufacturers and prescription drug plans under the Medicare prescription drug benefit unless the price concessions are either provided at the point of sale to beneficiaries or are reflected in cost-sharing requirements.
What just happenedOct 20, 2021
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseOct 19, 2021
- Oct 20, 2021Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Oct 19, 2021Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Oct 19, 2021IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Oct 19, 2021IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Oct 19, 2021IntroReferralIntro-H
Introduced in House
- Oct 19, 2021IntroReferral1000
Introduced in House